Factors Associated With Human Papillomavirus Vaccine Series Completion Among Adolescents
- PMID: 34256974
- PMCID: PMC9948546
- DOI: 10.1016/j.amepre.2021.04.031
Factors Associated With Human Papillomavirus Vaccine Series Completion Among Adolescents
Abstract
Introduction: Most cancers associated with the human papillomavirus are preventable through vaccination. However, adolescent series completion rates are at 75.8%. Two vaccine doses are recommended for adolescents, but factors influencing 2-dose series completion are not well explored. The purpose of this study is to examine individual-level and community-level factors associated with timely human papillomavirus vaccine series completion among adolescents in the Southeastern U.S.
Methods: Series completion was assessed from January 2018 to February 2019 among a cohort of adolescents initiating vaccination in 2017. Factors influencing overall series completion and timely series completion were assessed using multivariable logistic regression.
Results: Among the sample, 64.4% completed the vaccine series and 53.8% completed it timely (e.g., 14 months). Higher odds of series completion were among adolescents who were younger at vaccine initiation (AOR=1.94, 95% CI=1.50, 2.50), who traveled moderate distances to the clinic (AOR=1.62, 95% CI=1.03, 2.56), and who lived in low-deprivation neighborhoods (AOR=1.85, 95% CI=1.31, 2.60), and lower among Hispanic (AOR=0.62, 95% CI=0.45, 0.87) and non-Hispanic Black (AOR=0.66, 95% CI=0.54, 0.81) adolescents and among those without private insurance (AOR=0.68, 95% CI=0.56, 0.83). Timely series completion resulted in similar findings; however, lower odds were among Hispanic (AOR=0.63, 95% CI=0.43, 0.95) and non-Hispanic Black (AOR=0.68, 95% CI=0.50, 0.92) adolescents than among non-Hispanic other adolescents.
Conclusions: Individual-level and community-level factors continue to influence adolescent series completion, despite a reduction in doses. Future research is needed to understand racial/ethnic and regional disparities in human papillomavirus vaccine series completion and to develop interventions to promote series completion.
Copyright © 2021 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.
References
-
- HPV Vaccination for Cancer Prevention: Progress, Opportunities, and a Renewed Call to Action. A Report to the President of the United States from the Chair of the President’s Cancer Panel. Bethesda, MD: President’s Cancer Panel; 2018.
-
- Immunization and infectious diseases. HHS. https://www.healthypeople.gov/2020/topics-objectives/topic/immunization-.... Updated October 8, 2020. Accessed October 15, 2020.
-
- HPV vaccination information for health professionals. American Cancer Society. https://www.cancer.org/health-care-professionals/hpv-vaccination-informa.... Accessed October 15, 2020.
-
- HPV and cancer. Centers for Disease Control and Prevention. http://www.cdc.gov/cancer/hpv/statistics/cases.htm. Updated September 3, 2020. Accessed October 15, 2020.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources